Glucosamine chondroitin still fills pharmacy shelves and online carts across the United States, even as rheumatology leaders closed the door on it for common forms of osteoarthritis this month. The American College of Rheumatology board signed off on its 2026 osteoarthritis update on September 8. The document issues a strong recommendation against the ingredients, used alone or together, for knee, hip, and hand disease. Evidence certainty sits at low for glucosamine by itself and moderate for the paired formula. The shift marks a firmer line than the 2019 version of the same guidance.
Shoppers have not stepped away. Combination bottles continue to rank among the better-selling joint products on major retail sites. Adults over 50 drive most of the demand. Many report occasional stiffness and want a non-prescription option they can start without a clinic visit. Labels typically promise cartilage support. Federal rules classify the products as dietary supplements, so manufacturers do not need to prove benefit before sale.
How the Ingredients Reach the Bottle
Glucosamine is an amino sugar that cells use when they build cartilage molecules. Factories pull it from crab, shrimp, or lobster shells, or they grow it through fermentation. Two salts dominate the market: sulfate and hydrochloride. Chondroitin sulfate is a chain molecule already present in cartilage. Commercial supplies usually come from cow or marine cartilage. Capsules often combine both agents, sometimes with MSM or herbal extracts. Studied daily amounts cluster near 1,500 mg of glucosamine and 800 to 1,200 mg of chondroitin. Users commonly split that total across two or three doses.
What the Largest American Trial Found
The Glucosamine/Chondroitin Arthritis Intervention Trial enrolled 1,583 adults with painful knee osteoarthritis. Groups received glucosamine hydrochloride, chondroitin sulfate, both, a prescription anti-inflammatory, or an inactive pill. On the main pain score, neither supplement beat the inactive pill for the full study population. A smaller slice of participants with more severe pain showed a possible edge for the combination, yet that slice was not large enough to carry the overall result. The trial used the hydrochloride salt. European work that reported modest pain drops often used a patented crystalline sulfate instead. Store brands in the United States more often match the salt that failed to separate from placebo.
Small Gains That Stay Below Clinical Thresholds
An umbrella review released in August 2026 pooled prior glucosamine analyses for knee osteoarthritis. One pain scale showed a small statistical improvement. Function scores did not. Joint-space narrowing slowed by a margin that sat at or below the level most clinicians treat as meaningful to patients. Side-effect rates matched the inactive comparison. A separate randomized study published in September 2026 tested crystalline glucosamine sulfate against placebo and two other agents in adults with mild-to-moderate knee osteoarthritis. At 24 weeks the sulfate arm did not outperform placebo on the total symptom score. The pattern held at 36 weeks. Stomach complaints stayed mild and similar across arms.
Cognitive Signal From Health Records
A paper posted in Nature Metabolism on June 9, 2026, reviewed electronic records covering more than 24,000 people with Alzheimer-related dementia and nearly 42,000 with mild cognitive impairment. About 8 percent of each group had a record of glucosamine use. After basic demographic adjustment, users showed a 25 percent higher chance of moving from mild impairment to dementia over five years. Among those who already had dementia, use tracked with a 25 percent higher death risk at ten years. Lab work in the same project linked excess protein glycosylation to disease progression and suggested the supplement could feed that pathway. The design is observational. It cannot isolate the supplement from lower activity, frailty, or other unmeasured factors. Trade groups have pointed to older cohort work that did not show the same pattern.
Day-to-Day Tolerability and Specific Risks
Controlled trials generally describe the pair as easy to tolerate. Heartburn, loose stools, and headache appear most often. Serious events remain uncommon in published studies. Shellfish-sourced glucosamine warrants caution for anyone with a shellfish allergy. The main allergen lives in the meat, yet processing can leave traces. Fermentation-based versions avoid that raw material. Labels do not always name the source.
Warfarin presents a clearer interaction concern. Case reports sent to regulators describe higher clotting times and bleeding after people added glucosamine, sometimes with chondroitin, to the blood thinner. Clinicians often increase monitoring if a patient starts the supplement. Rare liver-enzyme changes have also led some specialists to advise extra care in people with existing liver disease.
Label Claims Versus Lab Results
Supplement makers set their own specifications. Independent checks continue to find gaps. A testing cycle covering 2025 and 2026 flagged roughly 12 percent of sampled joint products for delivering far less active ingredient than the front label stated. Shortfalls ranged from modest to severe. Buyers who feel a personal difference often stick with one brand, partly because content can shift between lots.
Where Clinical Advice Now Sits
Orthopedic groups in the United States have long discouraged these agents for knee osteoarthritis symptoms. The September rheumatology update extends a strong negative recommendation across knee, hip, and hand joints for both single ingredients and combination bottles. European panels have at times backed pharmaceutical-grade crystalline sulfate as a background choice. That distinction matters for American shoppers, because most mass-market bottles do not use the patented sulfate studied in those positive European trials.
Exercise, weight control, and standard anti-inflammatory medicines remain the options with clearer support in domestic guidance. The 2026 update also adds a conditional nod to GLP-1 receptor agonists, used with diet and activity, for adults who have knee osteoarthritis and obesity. That route targets joint load rather than cartilage chemistry.
Choices Facing Buyers This Fall
Healthy adults without a shellfish allergy and not on warfarin face low physical risk from a short trial at common doses. Proof of reliable pain relief or cartilage repair is weak. People who already live with cognitive impairment now have an additional observational flag to discuss with a clinician. Sales data show the category remains active. Individual decisions still rest on personal tolerance, cost, and a clear view of what the trials and the 2026 guidance actually show.
Drop your questions about joint supplements in the comments and return for the next round of research updates.